ADAPY Analyst Ratings & Price Targets

ADAPYADAPY

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

16 analysts·Moderate coverage

56%

Rating Distribution

Strong Buy

00%

Buy

956%

Hold

425%

Sell

319%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 10381% higher.

Bear Case

$1.00

+3604%

Consensus

$2.83

+10381%

Bull Case

$4.00

+14715%

Price Range16 analysts

Low

Consensus

High

$1.00

$4.00

Current Target

Current Price

$0.03

Upside to Target

$2.80

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.01(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:+24.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jul 30, 2024H.C. Wainwright

Adaptimmune initiated with a Buy at H.C. Wainwright

Target:$4.00

+192.0%from $1.37

May 30, 2024Scotiabank

Scotiabank starts Adaptimmune at Outperform ahead of 'imminent' launches

Target:$3.15

+211.9%from $1.01

May 17, 2024Mizuho Securities

Adaptimmune price target lowered to $3 from $9 at Mizuho

Target:$3.00

+150.0%from $1.20

May 16, 2024Barclays

Barclays Reiterates Underweight Rating on Adaptimmune Therapeutics plc (ADAP)

Target:$1.00

-16.7%from $1.20

Nov 14, 2022Wells Fargo

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3

Target:$3.00

+19.5%from $2.51

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance